PRE vs. CERO, FHLT, ARYD, FEMY, MRM, LEXX, NMTC, EVGN, PLUR, and OMIC
Should you be buying Prenetics Global stock or one of its competitors? The main competitors of Prenetics Global include CERo Therapeutics (CERO), Future Health ESG (FHLT), ARYA Sciences Acquisition Corp IV (ARYD), Femasys (FEMY), MEDIROM Healthcare Technologies (MRM), Lexaria Bioscience (LEXX), NeuroOne Medical Technologies (NMTC), Evogene (EVGN), Pluri (PLUR), and Singular Genomics Systems (OMIC). These companies are all part of the "medical" sector.
Prenetics Global (NASDAQ:PRE) and CERo Therapeutics (NASDAQ:CERO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, institutional ownership, dividends, media sentiment, valuation, analyst recommendations, profitability, earnings and risk.
CERo Therapeutics has a net margin of 0.00% compared to Prenetics Global's net margin of -193.60%. CERo Therapeutics' return on equity of 0.00% beat Prenetics Global's return on equity.
Prenetics Global received 5 more outperform votes than CERo Therapeutics when rated by MarketBeat users.
CERo Therapeutics has lower revenue, but higher earnings than Prenetics Global.
In the previous week, Prenetics Global had 1 more articles in the media than CERo Therapeutics. MarketBeat recorded 2 mentions for Prenetics Global and 1 mentions for CERo Therapeutics. CERo Therapeutics' average media sentiment score of 0.67 beat Prenetics Global's score of -0.25 indicating that CERo Therapeutics is being referred to more favorably in the news media.
Prenetics Global has a beta of -0.11, meaning that its share price is 111% less volatile than the S&P 500. Comparatively, CERo Therapeutics has a beta of -0.38, meaning that its share price is 138% less volatile than the S&P 500.
Prenetics Global currently has a consensus price target of $9.00, indicating a potential upside of 95.23%. Given Prenetics Global's higher probable upside, research analysts clearly believe Prenetics Global is more favorable than CERo Therapeutics.
25.0% of Prenetics Global shares are held by institutional investors. Comparatively, 29.6% of CERo Therapeutics shares are held by institutional investors. 7.8% of Prenetics Global shares are held by company insiders. Comparatively, 84.8% of CERo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Prenetics Global and CERo Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.
Get Prenetics Global News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Prenetics Global Competitors List
Related Companies and Tools
